Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.57 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | CDK4 | P11802 | 2/20 | 0.39 |
| ▸ | CCND1 | P24385 | 2/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31182057 | 1.00 | NFE2L2 (0.57) | NFE2L2CES2CES1CDK4CCND1 | |
| SCHEMBL706361 | 1.00 | NFE2L2 (0.57) | NFE2L2CES2CES1CDK4CCND1 | |
| SCHEMBL3720644 | 0.83 | NFE2L2 (0.57) | NFE2L2CDK4CCND1 | |
| SCHEMBL4291385 | 0.83 | NFE2L2 (0.57) | NFE2L2CDK4CCND1 | |
| SCHEMBL2343340 | 0.83 | NFE2L2 (0.57) | NFE2L2CDK4CCND1 | |
| SCHEMBL22039183 | 0.82 | ERN1 (0.42) | NFE2L2CDK4CCND1ERN1CCNB2 | |
| SCHEMBL21676110 | 0.80 | SMN1; SMN2 (0.42) | NFE2L2CDK4CCND1ERN1CA9 | |
| SCHEMBL21676108 | 0.80 | AMY1A (0.37) | NFE2L2CDK4CCND1CCNB2CDK1 | |
| SCHEMBL20074265 | 0.80 | CDK4 (0.37) | NFE2L2CDK4CCND1CCNB2CDK1 | |
| SCHEMBL18255048 | 0.80 | NFE2L2 (0.40) | NFE2L2CDK4CCND1ERN1CCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220235032-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2022-07-28 | — | — | US | disclosed |
| EP-3527562-B1 | MICROTUBULE PROTEIN INHIBITOR | SHENZHEN NEPTUNUS PHARMACEUTICAL RES INSTITUTE CO LTD (CN) | 2022-04-06 | — | — | EP | disclosed |
| EP-3967682-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020224656-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2020-11-12 | — | — | WO | disclosed |
| WO-2020224656-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2020-11-12 | — | — | WO | disclosed |
| US-10640492-B2 | Tubulin inhibitor | SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2020-05-05 | — | — | US | disclosed |
| EP-3527562-A1 | MICROTUBULE PROTEIN INHIBITOR | Shenzhen Neptunus Pharmaceutical Research Institute Co., Ltd. (CN) | 2019-08-21 | — | — | EP | disclosed |
| US-20190225595-A1 | TUBULIN INHIBITOR | SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2019-07-25 | — | — | US | disclosed |
| EP-2094267-B1 | 4-(1-AMINO-ETHYL)-CYCLOHEXYLAMINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-04-22 | — | — | EP | disclosed |
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| EP-1799674-A1 | NEW PIPERIDINE ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2007-06-27 | — | — | EP | disclosed |
| EP-1799676-A2 | NEW BICYCLIC ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2007-06-27 | — | — | EP | disclosed |
| US-7232833-B2 | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | NOVEXEL (FR) | 2007-06-19 | — | — | US | disclosed |
| WO-2007042325-A1 | ANTIBACTERIAL ACTIVE 5-CHINOLIN DERIVATIVE | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2007-04-19 | — | — | WO | disclosed |
| EP-1763527-A1 | 4-SUBSTITUTED QUINOLINE DERIVATIVES, METHOD AND INTERMEDIATES FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | NOVEXEL (FR) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006125974-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006038172-A1 | NEW PIPERIDINE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006032466-A2 | NEW BICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006010831-A1 | 4-SUBSTITUTED QUINOLINE DERIVATIVES, METHOD AND INTERMEDIATES FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | NOVEXEL (FR) | 2006-02-02 | — | — | WO | disclosed |
| US-20040224946-A1 | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | PAICS, SBDS, SORD | NFE2L2 2031/4885CES2 410/4885CES1 900/4885 |
| US-20040224946-A1 | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | HRH2, HRH1, HRH3 | NFE2L2 788/4885CES2 260/4885CES1 1189/4885 |
| US-20220235032-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | NFE2L2 3518/4885CES2 3077/4885CES1 476/4885 |
| US-20190225595-A1 | TUBULIN INHIBITOR | TUBB1, TUBB, TUBA1C | NFE2L2 3532/4885CES2 1919/4885CES1 2272/4885 |
| US-10640492-B2 | Tubulin inhibitor | TUBB1, TUBB, TUBA1C | NFE2L2 3532/4885CES2 1919/4885CES1 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.